Immunate

Human Coagulation Factor VIII and Human von Willebrand Factor, the active ingredient in Immunate, is a coagulation factor replacement presented as a solution for injection for intravenous use. It treats hemophilia A and von Willebrand disease by providing the missing clotting proteins.

GNH USA supplies Immunate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunate is used to replace deficient clotting proteins in inherited bleeding disorders. - Hemophilia A: restores factor VIII activity to achieve hemostasis during bleeding episodes and surgery. - Von Willebrand disease: supplies von Willebrand factor to improve platelet adhesion and stabilize factor VIII. - Peri‑operative management in patients with combined factor VIII/vWF deficiency: provides hemostatic coverage before, during, and after surgical procedures.

Immunate may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills, fever) - Headache - Nausea or vomiting - Arthralgia or muscle aches - Mild hypertension - Local site erythema or swelling

Serious or Rare Side Effects: - Development of inhibitory antibodies against factor VIII or von Willebrand factor - Anaphylactic or severe allergic reactions - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Renal dysfunction or acute kidney injury - Severe hypotension or shock - Transmission of blood‑borne pathogens (theoretical risk).

Before using Immunate, clinicians should consider several safety measures. - Monitor for inhibitor development: assess factor activity levels regularly. - Assess for hypersensitivity: observe patients during the first infusion for signs of allergic reaction. - Use with caution in patients with cardiovascular disease or a history of thrombosis. - Avoid in individuals with known hypersensitivity to plasma‑derived products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate can interact with other agents that affect coagulation.

Major Interactions (Avoid): - Concomitant use of other factor VIII or von Willebrand factor concentrates: may increase risk of excessive clot formation. - High‑dose procoagulant agents (e.g., activated prothrombin complex concentrate): heightened thrombosis risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, direct oral anticoagulants): may reduce the hemostatic efficacy of Immunate. - Antifibrinolytics (tranexamic acid, aminocaproic acid): may potentiate clot stability and increase thrombosis risk. - Immunosuppressive therapies: could affect inhibitor development and immune response.